Olema Pharmaceuticals, Inc. (OLMA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Olema Pharmaceuticals, Inc. (OLMA) closed at USD 6.80 on 2026-10-14, a change of -22 % over the past year, with a market capitalization of USD 601.11M.

Olema Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Olema Pharmaceuticals, Inc. key figures

Previous close

USD 6.80 (2026-10-14)

1-year change

-22 %

Market cap

USD 601.11M

Enterprise value

USD 143.7M

P/E ratio (trailing)

-3.32

P/E ratio (forward)

-2.61

EPS (trailing)

-2.07

EPS (forward)

-2.64

PEG ratio

n/a

Price to book

1.40

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

11.88

Employees

150

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Olema Pharmaceuticals, Inc. and compare it with other stocks.